Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series.

Thumbnail
View/Open
Accepted version (220.3Kb)
Date
2017-01
ICR Author
Gore, Martin
Larkin, James
Messiou, Christina
Marsden,
Turajlic, Samra
Author
Spain, L
Walls, G
Messiou, C
Turajlic, S
Gore, M
Larkin, J
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Background The efficacy and potential toxicity of rechallenge with combination ipilimumab and nivolumab has not been described. Retreatment of patients with immune checkpoint inhibitors in the setting of prior significant toxicity lacks evidence-based guidance.Methods We present the first three, consecutive patients who received re-treatment with combination ipilimumab and nivolumab for metastatic melanoma managed at our institution.Results Rechallenge with combination ipilimumab and nivolumab in the setting of prior grade 3 toxicity with initial combination therapy is feasible, and responses are seen. We highlight the fact that grade 3 toxicity is likely to recur, but if so, can be manageable.Conclusions Retreatment with ipi + nivo may be considered an option in carefully selected, well-informed patients. More research is required to delineate the benefits and risks with this approach.
URI
https://repository.icr.ac.uk/handle/internal/503
DOI
https://doi.org/10.1007/s00262-016-1926-2
Collections
  • Clinical Studies
Subject
Humans
Melanoma
Neoplasm Metastasis
Antineoplastic Combined Chemotherapy Protocols
Antibodies, Monoclonal
Adult
Aged
Middle Aged
Female
Male
Ipilimumab
Nivolumab
Research team
Melanoma and Kidney Cancer
Language
eng
Date accepted
2016-11-06
License start date
2017-01
Citation
Cancer immunology, immunotherapy : CII, 2017, 66 (1), pp. 113 - 117

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.